The research team set out to address a well-known therapeutic gap. Proton pump inhibitors and H2-receptor antagonists reduce gastric acid and relieve symptoms, but they do little to halt the underlying inflammatory cascade and cellular damage that perpetuate injury and slow healing. Prolonged use of these drugs has been linked to hypomagnesemia, renal complications, and infections such as Clostridium difficile, while antibiotic resistance increasingly undermines eradication therapy for Helicobacter pylori, the other major cause of ulcer disease. Live probiotics have shown promise as mucosal protectants, but they raise safety concerns for immunocompromised patients and pose practical problems of shelf life, stability, and standardization. Paraprobiotics—inactivated microbial cells or their structural components—sidestep many of these issues while, according to accumulating evidence, retaining much of the immunomodulatory activity of their living counterparts.

To prepare the paraprobiotic, the researchers grew B. lactis BB-12 anaerobically, concentrated the cells, and heated the suspension at 85 degrees Celsius for 15 minutes. Flow cytometry using the SYTO 9 and propidium iodide dyes confirmed that the treatment was decisive: 99.5 percent of the bacterial population showed the propidium iodide-positive, membrane-compromised signature of dead cells, with fewer than 0.2 percent remaining viable. The washed, non-viable preparation therefore represented intact dead cells carrying their structural arsenal of peptidoglycans, teichoic acids, and surface-layer proteins—the components now recognized as the principal effectors of paraprobiotic bioactivity—rather than a soup of soluble metabolites.

The experiment used fifty adult male Balb/c mice divided into five groups of ten. One group served as healthy controls; a second received a single oral dose of indomethacin, a non-steroidal anti-inflammatory drug that reliably induces severe gastric ulceration by inhibiting protective prostaglandins; and three treatment groups received lansoprazole, live B. lactis BB-12, or the heat-killed paraprobiotic five minutes before the ulcer-inducing dose. Six hours later, the animals were sacrificed and their stomachs examined. The results were dramatic. Indomethacin alone left hemorrhagic lesions covering 52.5 percent of the gastric mucosa, with a macroscopic damage score near the maximum of four. Lansoprazole reduced the ulcer area to 15.1 percent, an inhibition of 71.2 percent. The live probiotic achieved 58.9 percent inhibition, and the paraprobiotic 67.0 percent—statistically indistinguishable from the drug at the level of ulcer area.

Where the paraprobiotic clearly pulled ahead was in damage severity. Its macroscopic damage score of 1.02 was significantly lower not only than that of untreated ulcer mice but also lower than the scores of both the lansoprazole group and the live probiotic group. Histological examination told the same story. Under the microscope, indomethacin had devastated the mucosa with deep necrosis, hemorrhage, vascular occlusion, edema, and dense neutrophil infiltration, producing a total damage index of 3.95. Lansoprazole lowered that index to 2.49, but the live probiotic and the paraprobiotic outperformed the drug, driving the index down to 1.27 and 0.95 respectively, with mucosal architecture largely preserved and inflammation minimal.

Biochemical analyses revealed how the treatments were shielding the tissue. Indomethacin severely depleted the stomach’s antioxidant defenses—superoxide dismutase, catalase, and reduced glutathione all fell sharply—while malondialdehyde, a marker of lipid peroxidation, surged. Both bacterial preparations restored the antioxidant enzymes to near-control levels and suppressed lipid peroxidation more effectively than lansoprazole did. Myeloperoxidase activity, a proxy for neutrophil infiltration, was similarly tamed. In the blood, the picture was one of systemic immune reprogramming: the cytokine storm of tumor necrosis factor-alpha and interleukin-6 triggered by indomethacin was damped most powerfully by the paraprobiotic, which outperformed both the drug and the live probiotic, while the anti-inflammatory cytokine interleukin-10, crushed by the ulcer-inducing drug, was fully restored by both bacterial treatments.

The centerpiece of the study, however, lay in its Western blot analysis of the PANoptosis pathway—a term coined in 2019 to describe a lytic cell death program that simultaneously engages pyroptosis, apoptosis, and necroptosis through a multi-protein complex called the PANoptosome. In the ulcerated stomachs, all three arms were firing at once. The NLRP3 inflammasome was upregulated, caspase-1 was cleaved into its active form, and its substrates—gasdermin D, which punches lethal pores in cell membranes, and interleukin-1β, which fans the inflammatory fire—were both processed at high levels, marking pyroptosis. The DNA sensor ZBP1 was elevated, caspase-8 and the executioner caspase-3 were activated, and gasdermin E was cleaved, a step thought to convert otherwise quiet apoptosis into inflammatory secondary necrosis. Finally, the necroptosis kinases RIPK3 and MLKL were heavily phosphorylated, indicating that the third death program had also been engaged.

All three treatments blunted this coordinated cell death response, but the bacterial preparations, and especially the paraprobiotic, were consistently the stronger inhibitors. The paraprobiotic suppressed cleaved caspase-1 and cleaved interleukin-1β significantly more than the live probiotic, showed the most potent anti-apoptotic effect on ZBP1 and caspase-3, and reduced phosphorylated RIPK3 more than lansoprazole. Because a therapy targeting only one death pathway might simply leave the others to finish the job, the authors argue that the paraprobiotic’s ability to simultaneously restrain NLRP3, ZBP1, and RIPK3 signaling makes it a broad-spectrum cell death regulator—one that intercepts stress signals at their source rather than downstream. This is, according to the researchers, the first evidence that gastric ulcer pathology is driven by this integrated death network and that a paraprobiotic can inhibit it.

The implications are considerable. A dead bacterial preparation that matches or beats a frontline drug, carries no risk of infection, resists storage and manufacturing pitfalls, and works through rapid mucosal interaction rather than long-term colonization could reshape how inflammatory gastrointestinal disease is prevented and treated. The authors are careful to note the limits of their work: the study used a single acute model, a single strain, and a six-hour window, and it examined key regulatory proteins rather than the full PANoptosome complex, which includes adaptors such as ASC and FADD. Whether the effect extends to ulcers caused by H. pylori or stress, and whether it holds in other species and in humans, remains to be shown. Still, the message is provocative: the protective power of a probiotic may not require the microbe to be alive at all—only intact enough for its surface molecules to talk the gut’s immune system out of destroying itself.

Subject of Research: Gastroprotective effects of heat-inactivated Bifidobacterium lactis BB-12 paraprobiotics against indomethacin-induced gastric ulcer through inhibition of PANoptosis

Article Title: Paraprobiotics Derived From Bifidobacterium animalis Subsp. Lactis BB‐12 Attenuates Indomethacin‐Induced Gastric Ulcer by Inhibiting the PANoptosis Pathway

Article References: Yavaş, A., Özkiran, E., & Akan, E. (2026). Paraprobiotics Derived From Bifidobacterium animalis Subsp. Lactis BB ‐12 Attenuates Indomethacin‐Induced Gastric Ulcer by Inhibiting the PANoptosis Pathway. Food Science & Nutrition, 14(10), Article e72397. https://doi.org/10.1002/fsn3.72397

Image Credits: AI Generated

DOI: 10.1002/fsn3.72397

Keywords: paraprobiotics, Bifidobacterium lactis BB-12, gastric ulcer, PANoptosis, pyroptosis, apoptosis, necroptosis, indomethacin, oxidative stress, NLRP3 inflammasome, probiotics, gastroprotection